What is NAC (N-Acetyl-L-Cysteine)? (Dr Eric Berg)
https://youtu.be/oPdGOrqTfhA
What is NAC good for? (and How Much to Take?)
Covid Vaccines and ‘Emergency Use’ Authorization Explained.
David Dodd discussing COVID-19 Vaccines and 'Emergency Use' Authorization
https://youtu.be/Ppx8gQyYj8s?si=ACG31q97BSIBif4z&t=30
Revive’s Quarterly Report, Discussion, and a Video!
With 5,000 hospitalizations reported daily (150,000 a month), contracting Covid is not something to be taken lightly - after you get it....
Revive Therapeutics Gains 25% on Positive FDA Comments.
The Company stated yesterday that it "has received positive comments from the FDA in regard to the Company’s request to determine and...
Bavarian Nordic (BVNRY) Bags $119 Million Order from Joe Biden.
We Were up 80% on Bavarian For a Little While There. The Stock Looks Better Today, Then When we Originally Added...
Could Bucillamine be the Key to Preventing Lockdowns in Places Like North Korea?
Revive Therapeutics Nears FDA-EUA Approval or Non-approval, for Bucillamine its Novel Anti-inflammatory and Antioxidant. Bucillamine 'Boosts' Glutathione, a Natural Substance Found...
Institutional Analyst Newsletter. April 14, 2022.
Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict
LIVE QUOTE
Report on Citius Pharma (CTXR): North Shore Research Issues a $10 Price Target, a...
We're Up 181% on Citius Pharma (CTXR), Despite its Being Well Below it's Recent High of $4.30. We Now Have Two $10...
Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict for Its Novel Covid...
Two Binary Events Directly Ahead.
As in Months Away, not Years. Share Price up 76% During April.
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
TORONTO, April 11, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...
Latest article
Adding Quantum Pharmaceutical (QNTM) $4.10 to Reverse Split Stock Watch List.
119% Gain Post Split
Nine Page Summary Report on GeoVax (GOVX)
This is a great long-term story. We’re telling you.
(March 2024) When we finished writing our earlier...
GeoVax (GOVX) Provides First Half 2024 Business Update.
Award of BARDA Project NextGen contract represents a significant milestone event;
Total value...
